Celera Licenses Protein IP for Lung Cancer Dx
October 30th, 2009
Celera said today that it has licensed the rights to use Medical Therapies Limited’s patent portfolio for the protein midkine in its lung cancer diagnostics programs.
Under the exclusive license with Sydney-based Medical Therapies, Celera will pay up front and milestone payments and royalties on product sales over the life of the patents. Specific financial details were not disclosed by the firms.